Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Inflammatory Disease and Oncology Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for CXCL2 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CXCL2 Recombinant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 expressed for native conformation. |
View CXCL2 Products |
| Gene Delivery | CXCL2 Promise-ORF / Lentivirus Full-length ORF for stable cell line generation and expression validation. |
View CXCL2 Products |
| Benchmark Ab | Anti-CXCL2 Recombinant Antibody Recombinant positive control derived from clinical-grade reference sequences. |
View CXCL2 Products |
| Validator | CXCL2 siRNA Set Target-specific knockdown verification in functional assays. |
View CXCL2 Products |
| Related Target A | CXCR2 Primary G-protein coupled receptor for CXCL2, mediating neutrophil chemotaxis. Recommend Lentivirus for stable cell line development. |
View CXCR2 Products |
| Related Target B | CXCL1 Close homolog sharing the CXCR2 receptor; critical for cross-reactivity and selectivity profiling. |
View CXCL1 Products |
| Related Target C | CXCL8 Major CXCR1/2 ligand; essential for counter-screening to establish candidate selectivity. |
View CXCL8 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| High sequence homology among CXC chemokines | Homolog panel proteins (CXCL1, CXCL2, CXCL8) strictly verified by mass spectrometry and sequence-verified to ensure zero cross-contamination. |
| Receptor binding assay dependency on active conformation | HEK293 expressed human CXCL2 ensures native post-translational modifications and correct folding compared to E. coli sources. |
| Lack of standardized positive controls | Sequence-verified clinical benchmark antibodies (biosimilars) included to calibrate neutralization assays. |
| Target specificity validation | Sequence-specific siRNA sets included for target knockdown and loss-of-function specificity checks in primary cell assays. |
Live CXCL2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CXCL2-targeted therapeutics is intensifying, with major players shifting focus from traditional monoclonal antibodies to combination regimens targeting the tumor microenvironment (TME). CXCL2 is a critical chemokine recruiting myeloid-derived suppressor cells (MDSCs) and tumor-associated neutrophils (TANs), which drive resistance to anti-PD-1/PD-L1 therapies. As first-generation CXCR2 small molecule antagonists reach clinical milestones, the next wave of R&D is targeting the specific neutralization of CXCL2/CXCL1 ligands to avoid systemic toxicities associated with broad receptor blockade.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Neutralizing mAb | Academic/Biotech Consortiums | Solid Tumors, Metastatic Colorectal Cancer | Ligand neutralization assay (Requires ultra-pure CXCL2 ECD protein with endotoxin controlled <1 EU/ug) |
| Small Molecule (GPCR Antagonist) | Dompe Farmaceutici, AstraZeneca | Type 1 Diabetes, Inflammatory Disorders, Oncology | Receptor activation & binding assays (Requires CXCR2 Lentivirus for stable cell line generation) |
| Bispecific Antibodies | Emerging Biopharma | Immuno-oncology (Overcoming PD-1 resistance) | Dual-targeting selectivity assays (Requires sequence-verified CXCL1 and CXCL2 recombinant proteins) |